Agios Pharmaceuticals
a public American pharmaceutical company
AGIO Nasdaq
ISIN US00847X1046 SEC CIK 1439222 LEI 529900ONJHY8EOGYT555
Follow Agios Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$55.4M
+330% vs same quarter last year
Net income
−$65M
+37.1% vs same quarter last year
EPS, diluted
−$1.09
+38.8% vs same quarter last year
Operating cash flow
−$59.2M
+32.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $54M | −$413M |
| FY24 | $36.5M | $674M |
| FY23 | $26.8M | −$352M |
| FY22 | $14.2M | −$232M |
| FY21 | $0 | $1.6B |
| FY20 | $0 | −$327.4M |
| FY19 | $117.9M | −$411.5M |
| FY18 | $94.4M | −$346M |
| FY17 | $43M | −$314.7M |
| FY16 | $69.9M | −$198.5M |
| FY15 | $59.1M | −$117.7M |
| FY14 | $65.4M | −$53.5M |
| FY13 | $25.5M | −$39.4M |
| FY12 | $25.1M | −$20.1M |
| FY11 | $21.8M | −$23.7M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 88.3% | −873.9% | −764.4% |
| FY24 | 88.6% | −1166.5% | 1846.7% |
| FY23 | 89.3% | −1459.5% | −1312.3% |
| FY22 | 88% | −2732.1% | −1629.2% |
| FY21 | - | - | - |
| FY20 | - | - | - |
| FY19 | 98.9% | −268.2% | −349% |
| FY18 | 98.5% | −384% | −366.6% |
| FY17 | 100% | −745.8% | −731.6% |
| FY16 | 100% | −287.6% | −284% |
| FY15 | - | −200.8% | −199.1% |
| FY14 | - | −82.8% | −81.9% |
| FY13 | - | −152.2% | −154.2% |
| FY12 | - | −91.6% | −80.1% |
| FY11 | - | −76.2% | −108.6% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$377.3M |
| FY24 | −$391.5M |
| FY23 | −$297.1M |
| FY22 | −$314.4M |
| FY21 | −$413.1M |
| FY20 | −$304.9M |
| FY19 | −$382.7M |
| FY18 | −$311.4M |
| FY17 | −$289.9M |
| FY16 | $28.6M |
| FY15 | −$97.1M |
| FY14 | −$61.6M |
| FY13 | −$57.7M |
| FY12 | −$51M |
| FY11 | −$17.1M |
- Agios Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Agios Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −764.4% | −30.6% |
| FY24 | 1846.7% | −47% |
| FY23 | −1312.3% | −58% |
| FY22 | −1629.2% | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | −349% | −46.2% |
| FY18 | −366.6% | −49.6% |
| FY17 | −731.6% | −45.9% |
| FY16 | −284% | −36% |
| FY15 | −199.1% | −37.8% |
| FY14 | −81.9% | −35.5% |
| FY13 | −154.2% | −37.1% |
| FY12 | −80.1% | −29.1% |
| FY11 | −108.6% | −27.9% |